Evaluating the Readability of Clinical Trial Content for Patients on Pharmaceutical Company Websites [0.03%]
评估制药公司网站上临床试验内容的可读性以患者的视角进行评判
Christopher Felix Brewer
Christopher Felix Brewer
Background and objectives: Efficient and informed patient recruitment, followed by successful enrolment, is essential for the conduct of clinical trials. As major stakeholders in the research process, pharmaceutical compa...
Studies of Cannabinoid-Based Products in ClinicalTrials.gov: A Scoping Review [0.03%]
临床试验备案资讯网站中大麻素制品研究的范畴综述
Margaret Haney,Ziva D Cooper,Hannah VanLaanen et al.
Margaret Haney et al.
Background and objectives: There is increased interest in using cannabinoid-based products for therapeutic purposes. Because of unique regulatory challenges associated with these products, understanding the state of curre...
Elaine Lau,Alicia Koo,Han Byul Kang et al.
Elaine Lau et al.
Background: The growing number of indications and patent expirations for biologic drugs has created opportunities for market expansion of biosimilars; however, biosimilar uptake in children has lagged behind adults. There...
Joint Clinical Assessments in Europe: Implications for Market Access, Reimbursement, and National HTA Alignment [0.03%]
欧洲联合临床评估:对市场准入、报销和国家卫生技术评估的影响
Amit Dang,Sameera Tak
Amit Dang
The Joint Clinical Assessment is a crucial development under the European Union Health Technology Assessment Regulation (EU HTAR, 2021/2282), aimed at standardizing clinical assessments across the Member States. This review explores the opp...
Clearing the Mist: The Distinct Roles of Transparency and Explainability for Using AI in Drug and Device Development [0.03%]
拨开迷雾:在药品和器械研发中使用AI的透明性和可解释性的不同作用
Timothé Ménard,Katrina A Bramstedt
Timothé Ménard
The Evolution of Medical Affairs Central Teams: Shaping Strategic Action and Driving Healthcare Transformation Through Scientific Interaction [0.03%]
医学事务中心团队的演变:通过科学互动塑造战略性行动并推动医疗转型
Manuel Leal Beckouche,Gustavo Resler Plat,Jorge A Marinich et al.
Manuel Leal Beckouche et al.
The evolving role of Medical Affairs (MA) has positioned this department as a key element in the development and lifecycle management of pharmaceutical products. In response to internal and external assessments, AstraZeneca (AZ) Spain imple...
Evaluating the MAPA Medical Affairs Competency Framework: Insights from Amgen-Led Pilot Study in Australia, Japan and China [0.03%]
MAPA医学事务能力模型评价:安进公司澳日中三国试点研究的启示
Riaz Abbas,Orin Chisholm,Victoria Elegant et al.
Riaz Abbas et al.
Background and objectives: The biopharmaceutical industry requires fast role adaptation and comprehensive competency development to thrive in a rapidly evolving and challenging environment. Whilst competency frameworks ex...
Leping Kong,Ben Grobman,Arian Mansur et al.
Leping Kong et al.
Tissue-agnostic therapies, which target molecular alterations across cancer types, have been approved by the US Food and Drug Administration (FDA) since 2017. These approvals were based on clinical trials enrolling patients across diverse t...
Anthony W Fox
Anthony W Fox